Discontinuation of tyrosine kinase inhibitor therapy in CML patients outside of clinical trials: Interim results of the German CML VI trial
K. Kohlbrenner, N. Galuschek,A. Fabarius,M. Reiser, K. Fenchel, E. Esseling, T. Gohler, R. B. Kuhn, R. Depenbusch, I Azeh,E. Engel,R. Hansen,M. Haenel, J. Anhuf, P. Jehner, M. Abu Samra, M. Ritter,N. Gattermann, H. Pelz, S. Fuxius, B. Oswald,G. M. Baerlocher,T. H. Bruemmendorf, D. Heim,P. le Coutre, A. Burchert,D. Niederwieser, H. Tesch,W. -K Hofmann, A. Hochhaus, R. Hehlmann,S. Saussele ONCOLOGY RESEARCH AND TREATMENT（2021）
AI 理解论文
溯源树
样例
